Entrada Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-143.8M | $65.6M | $-6.7M | $-94.6M | $-51.2M | $-26.5M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $4.1M | $3.8M | $2.8M | $1.9M | $1.1M | $326.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $19.6M | $17.9M | $13.1M | $9.9M | $2.5M | $325.0K |
| Net Cash from Operating Activities | $-128.5M | $-41.6M | $139.8M | $-93.8M | $-50.9M | $-25.6M |
| Investing Activities | ||||||
| Capital Expenditures | $1.0M | $3.2M | $5.6M | $2.9M | $4.6M | $2.3M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $116.8M | $-27.8M | $-138.4M | $-148.7M | $-4.6M | $-2.3M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $887.0K | $103.0M | $21.0M | $479.0K | $307.5M | $50.1M |
| Net Change in Cash | $-10.8M | $33.6M | $22.4M | $-242.0M | $252.0M | $22.2M |
| Free Cash Flow | $-129.6M | $-44.7M | $134.2M | $-96.7M | $-55.4M | $-27.9M |